EUVIMEDEUVIMED entdecken
Editorial

Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis

Makito Miyake iD

International Journal of Urology · 2026-11 · 33 (11)

DOI: 10.1111/iju.70699 ↗

Kurz gefasst

Editorial in der Zeitschrift International Journal of Urology, online erschienen am 03.11.2026. Verfasst von Makito Miyake. Beteiligte Einrichtung: Department of Urology, Nara Medical University, Kashihara, Nara, Japan. Die Arbeit nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

bladder cancercopula modelenfortumab vedotinindependent drug actionpembrolizumab

Autor:innen und Institutionen

  • Department of Urology, Nara Medical University, Kashihara, Nara, Japan.

ORCID-Profile: Makito Miyake

Zitieren

APA

Miyake, M. (2026). Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis. International Journal of Urology, 33(11). https://doi.org/10.1111/iju.70699

Vancouver

Miyake M. Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis. International Journal of Urology. 2026;33(11). doi:10.1111/iju.70699

BibTeX
@article{Miyake2026,
  author = {Miyake, Makito},
  title = {Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis},
  journal = {International Journal of Urology},
  year = {2026},
  volume = {33},
  number = {11},
  doi = {10.1111/iju.70699}
}
Kostenlos starten →